ONSET AND DURABILITY OF EFFICACY OF BELIMUMAB ADMINISTERED SUBCUTANEOUSLY PLUS STANDARD OF CARE MEDICATIONS TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN A PHASE III TRIAL

被引：0
|
作者：
Doria, A. [1 ]
Stohl, W. [2 ]
Schwarting, A. [3 ]
Hammer, A. [4 ]
Fox, N. I. [5 ]
Groark, J. [6 ]
Bass, D. [6 ]
Pobiner, B. [4 ]
Edwards, L. [7 ]
Eastman, W. [4 ]
Gordon, D. [6 ]
机构：
[1] Univ Padua, Div Rheumatol, I-35100 Padua, Italy
[2] Univ Southern Calif, Keck Sch Med, Div Rheumatol, Los Angeles, CA USA
[3] Acura Kliniken, Bad Kreuznach, Germany
[4] GlaxoSmithKline, Res Triangle Pk, NC USA
[5] GlaxoSmithKline, Rockville, MD USA
[6] GlaxoSmithKline, Philadelphia, PA USA
[7] Parexel, Res Triangle Pk, NC USA
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2016年 / 34卷 / 04期
关键词：
systemic lupus erythematosus; clinical trial; belimumab;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S7:04
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [1] Clinical and Laboratory Correlates of Response in a Phase 3 Clinical Trial of Belimumab or Placebo Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)
    van Vollenhoven, Ronald F.
    Stohl, William
    Furie, Richard
    Fox, Norma Lynn
    Groark, James
    Bass, Damon
    Kurtinecz, Milena
    Pobiner, Bonnie
    Eastman, William
    Gonzalez-Rivera, Tania
    Gordon, David
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [2] A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)
    Stohl, William
    Schwarting, Andreas
    Okada, Masato
    Scheinberg, Morton
    Doria, Andrea
    Hammer, Anne
    Kleoudis, Christi
    Bass, Damon
    Groark, James
    Fox, Norma Lynn
    Roth, David
    Gordon, David
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [3] SUSTAINED SAFETY AND EFFICACY OVER 10 YEARS WITH BELIMUMAB (BEL) PLUS STANDARD SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) THERAPY (SOC) IN PATIENTS WITH SLE
    Wallace, D. J.
    Ginzler, E. M.
    Merrill, J. T.
    Furie, R. A.
    Stohl, W.
    Chatham, W.
    Weinstein, A.
    Mckay, J.
    McCune, W. J.
    Petri, M.
    Fettiplace, J.
    Roth, D.
    Ji, B.
    Heath, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 150 - 151
  • [4] Subcutaneous Belimumab Plus Standard of Care Demonstrated Improvement in Multiple Organ Domains Versus Placebo Plus Standard of Care in Patients with Active Systemic Lupus Erythematosus (SLE)
    Doria, Andrea
    Pobiner, Bonnie
    Eastman, William
    Kurtinecz, Milena
    Hammer, Anne
    Groark, James
    Bass, Damon
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [5] Efficacy and Safety of Belimumab Plus Standard Therapy in Patients With Systemic Lupus Erythematosus: A Meta-analysis
    Wei, Li-qiang
    Liang, Yong-gang
    Zhao, Yong
    Liang, Hui-tao
    Qin, Dong-chun
    She, Ming-cong
    CLINICAL THERAPEUTICS, 2016, 38 (05) : 1134 - 1140
  • [6] Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus
    Wallace, Daniel J.
    Ginzler, Ellen M.
    Merrill, Joan T.
    Furie, Richard A.
    Stohl, William
    Chatham, W. Winn
    Weinstein, Arthur
    McKay, James D.
    McCune, W. Joseph
    Petri, Michelle
    Fettiplace, James
    Roth, David A.
    Ji, Beulah
    Heath, Amy
    ARTHRITIS & RHEUMATOLOGY, 2019, 71 (07) : 1125 - 1134
  • [7] Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus
    Struemper, Herbert
    Thapar, Mita
    Roth, David
    CLINICAL PHARMACOKINETICS, 2018, 57 (06) : 717 - 728
  • [8] Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus
    Herbert Struemper
    Mita Thapar
    David Roth
    Clinical Pharmacokinetics, 2018, 57 : 717 - 728
  • [9] THE EFFICACY OF BELIMUMAB (BEL) AS A SPARING CORTICOSTEROID AGENCY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
    Inoue, K.
    Misaki, K.
    Dobashi, N.
    Yabe, M.
    Mako, Y.
    Tarutani, Y.
    Imaizumi, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1343 - 1343
  • [10] Application of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients
    Ceccarelli, F.
    Picciariello, L.
    Natalucci, F.
    Moretti, V.
    Spinelli, F. R.
    Alessandri, C.
    Conti, F.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (07) : 1491 - 1494
12345